Motor neuron synapses with muscle fiber via electrical impulse transmission and neurotransmitter release, forming neuromuscular junctions , motor neuron, neuroscience

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Joshua Newman, Phillipe Corcia, Angela Genge

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a terminal condition with a typical life expectancy of 2–5 years from symptom onset. […]

touchREVIEWS in Neurology. 2025;21(1):Online ahead of journal publication

Neurometabolic Disease

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

Published Online: Jul 22nd 2014

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis.

This Content is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]

Related Videos in Neurometabolic Disease

Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) describes the impact increased migration has had on the pathophysiology of neurological conditions and the need to increase awareness of this amongst neurologists. Questions 1. ...

Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) discusses the unique challenges that rare neurological diseases bring and how the EAN have a Task Force focused on this important area. Questions 1. Could ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

Günther Deuschl (EAN President; Professor of Neurology, Department of Neurology, University Hospital Schleswig-Holstein, Kiel Campus, Germany) kindly took the time to discuss with us the burden of neurological diseases in Europe, including disparities across our continent, and how the ...

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

Thapanee Somboon (Cleveland Clinic, OH) talks us through the key findings of her two presentations, which focused on the prevalence of high risk obstructive sleep apnea and insomnia in neurological populations (abstract available here) and the performance of sleep apnea ...

New Antisense Therapy in Development for Pompe Disease

In this exclusive interview during WORLDSymposium 2015, Nicholas Clayton, MSc, staff scientist at Genzyme Corporation discusses the exciting new data he and his colleagues presented on antisense therapy that is in development to treat patients with Pompe disease.

Niemann-Pick Disease Type C

Dr. Marc Patterson a pediatric neurologist at Mayo Clinic discusses Niemann-Pick disease type C.

Pompe Disease

Priya Kishnani, MD, professor of Pediatrics at Duke University School of Medicine and practicing geneticist at Duke Children's Hospital discusses our current understanding of the pathophysiology and management of Pompe disease.

New Treatment Option for Niemann-Pick Type B Disease

Beth Thurberg, MD, PhD, vice president of Pathology at Genzyme Corporation discusses the results of clinical trial looking at clearance of sphingomyelin with recombinant human acid sphingomyelinase administration in patients with Niemann-Pick Type B disease. ...

New Treatment Option for Niemann-Pick Type B

Looking at clearance of sphingomyelin with recombinant human acid sphingomyelinase administration in patients with Niemann-Pick Type B disease. ...

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick type C disease

For patients with Niemann-Pick type C (NPC) disease, the test will make it possible to begin treatment earlier, when it is more likely to improve quality of life. The fatal genetic disorder frequently takes years to diagnose, and earlier detection ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Learning Activities

Journals

Specialities

SOD1-ALS from Gene Discovery to Targeted Therapeutics: A Comprehensive Review

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

This Content is for
Members Only

Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick Disease Type C

Pompe Disease

New Treatment Option for Niemann-Pick Type B Disease

New Treatment Option for Niemann-Pick Type B

New Antisense Therapy in Development for Pompe Disease

Niemann-Pick type C disease

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Learning Activities

Journals

Specialities

Trending Topic

Connect With Us:

Anti-NMDA Receptor Encephalitis- the clinical criteria of early diagnosis

This Content is forMembers Only

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only